Recent advances in precision medicine for the treatment of anaplastic thyroid cancer

References

• American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer, Cooper DS, Doherty GM, et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19(11):1167–1214.
   PubMed Web of Science ®Google Scholar
• Key statistics for thyroid cancer. american cancer society. Available from: https://www.cancer.org/cancer/thyroid-cancer/about/key-statistics.html. [cited October 2018]
   Google Scholar
• Cancer Facts & Figures. American cancer society. Atlanta: American Cancer Society; 2016.
   Google Scholar
• Sherman SI. Thyroid carcinoma. Lancet. 2003;361(9356):501–511.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, Baldini E, et al. The safety and efficacy of vandetanib in the treatment of progressive medullary thyroid cancer. Expert Rev Anticancer Ther. 2016;16(11):1109–1118.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Bocci G, Di Desidero T, et al. Vandetanib has antineoplastic activity in anaplastic thyroid cancer, in vitro and in vivo. Oncol Rep. 2018;39(5):2306–2314.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Bocci G, Di Desidero T, et al. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo. Oncol Rep. 2018;39(5):2225–2234.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Thiazolidinediones and antiblastics in primary human anaplastic thyroid cancer cells. Clin Endocrinol (Oxf). 2009;70(6):946–953.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Primary cell cultures from anaplastic thyroid cancer obtained by fine-needle aspiration used for chemosensitivity tests. Clin Endocrinol (Oxf). 2008;69(1):148–152.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Ferrari SM, Fallahi P, et al. Evaluation of the sensitivity to chemotherapeutics or thiazolidinediones of primary anaplastic thyroid cancer cells obtained by fine-needle aspiration. Eur J Endocrinol. 2008;159(3):283–291.
   PubMed Web of Science ®Google Scholar
• Miccoli P, Materazzi G, Antonelli A, et al. New trends in the treatment of undifferentiated carcinomas of the thyroid. Langenbecks Arch Surg. 2007;392(4):397–404.
   PubMed Web of Science ®Google Scholar
• Liu JW, Chen C, Loh EW, et al. Tyrosine kinase inhibitors for advanced or metastatic thyroid cancer: a meta-analysis of randomized controlled trials. Curr Med Res Opin. 2018;34(5):795–803.
   PubMed Web of Science ®Google Scholar
• Samimi H, Fallah P, Naderi Sohi A, et al. Precision medicine approach to anaplastic thyroid cancer: advances in targeted drug therapy based on specific signaling pathways. Acta Med Iran. 2017;55(3):200–208.
   PubMedGoogle Scholar
• Kebebew E, Greenspan FS, Clark OH, et al. Anaplastic thyroid carcinoma. Treatment outcome and prognostic factors. Cancer. 2005;103(7):1330–1335.
   PubMed Web of Science ®Google Scholar
• Samimi H, Zaki Dizaji M, Ghadami M, et al. Essential genes in thyroid cancers: focus on fascin. J Diabetes Metab Disord. 2013;12(1):32.
   PubMedGoogle Scholar
• Smith N, Nucera C. Personalized therapy in patients with anaplastic thyroid cancer: targeting genetic and epigenetic alterations. J Clin Endocrinol Metab. 2015;100(1):35–42.
   PubMed Web of Science ®Google Scholar
• Miccoli P, Antonelli A, Spinelli C, et al. Completion total thyroidectomy in children with thyroid cancer secondary to the Chernobyl accident. Arch Surg. 1998;133(1):89–93.
   PubMedGoogle Scholar
• Ferrari SM, Ruffilli I, Centanni M, et al. Lenvatinib in the therapy of aggressive thyroid cancer: state of the art and new perspectives with patents recently applied. Recent Pat Anticancer Drug Discov. 2018;13(2):201–208.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Miccoli P, Fallahi P, et al. Role of neck ultrasonography in the follow-up of children operated on for thyroid papillary cancer. Thyroid. 2003;13(5):479–484.
   PubMed Web of Science ®Google Scholar
• Akaishi J, Sugino K, Kitagawa W, et al. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid. 2011;21(11):1183–1189.
   PubMed Web of Science ®Google Scholar
• Are C, Shaha AR. Anaplastic thyroid carcinoma: biology, pathogenesis, prognostic factors, and treatment approaches. Ann Surg Oncol. 2006;13(4):453–464.
   PubMed Web of Science ®Google Scholar
• De Crevoisier R, Baudin E, Bachelot A, et al. Combined treatment of anaplastic thyroid carcinoma with surgery, chemotherapy, and hyperfractionated accelerated external radiotherapy. Int J Radiat Oncol Biol Phys. 2004;60(4):1137–1143.
   PubMed Web of Science ®Google Scholar
• Pinto N, Black M, Patel K, et al. Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. J Oncol. 2014;2014:936285.
   PubMedGoogle Scholar
• Smallridge RC, Ain KB, Asa SL, et al. American thyroid association guidelines for management of patients with anaplastic thyroid cancer. Thyroid. 2012;22(11):1104–1139.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer. Curr Genomics. 2011;12(8):626–631.
   PubMed Web of Science ®Google Scholar
• Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer. 2009;16(1):17–44.
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12(2):245–262.
   PubMed Web of Science ®Google Scholar
• Perri F, Pezzullo L, Chiofalo MG, et al. Targeted therapy: a new hope for thyroid carcinomas. Crit Rev Oncol Hematol. 2015;94(1):55–63.
   PubMed Web of Science ®Google Scholar
• Duquette M, Sadow PM, Lawler J, et al. Thrombospondin-1 silencing down-regulates integrin expression levels in human anaplastic thyroid cancer cells with BRAF(V600E): new insights in the host tissue adaptation and homeostasis of tumor microenvironment. Front Endocrinol (Lausanne). 2013;4:189.
   PubMedGoogle Scholar
• Nucera C, Lawler J, Parangi S. BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression. Cancer Res. 2011;71(7):2417–2422.
   PubMed Web of Science ®Google Scholar
• Lee J, Hwang JA, Lee EK. Recent progress of genome study for anaplastic thyroid cancer. Genomics Inform. 2013;11(2):68–75.
   PubMedGoogle Scholar
• Murugan AK, Xing M. Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res. 2011;71(13):4403–4411.
   PubMed Web of Science ®Google Scholar
• Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nat Rev Cancer. 11(11):761–774.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE. Thyroid carcinoma: molecular pathways and therapeutic targets. Mod Pathol. 2008;21(2):S37–S43. Suppl2.
   PubMedGoogle Scholar
• Nikiforova MN, Nikiforov YE. Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 2008;8(1):83–95.
   PubMed Web of Science ®Google Scholar
• Ruggeri RM, Campennì A, Baldari S, et al. What is new on thyroid cancer biomarkers. Biomark Insights. 2008;3:237–252.
   PubMedGoogle Scholar
• Penna GC, Vaisman F, Vaisman M, et al. Molecular markers involved in tumorigenesis of thyroid carcinoma: focus on aggressive histotypes. Cytogenet Genome Res. 2016;150(3–4):194–207.
   PubMed Web of Science ®Google Scholar
• Su X, Jiang X, Wang W, et al. Association of telomerase reverse transcriptase promoter mutations with clinicopathological features and prognosis of thyroid cancer: a meta-analysis. Onco Targets Ther. 2016;9:6965–6976.
   PubMed Web of Science ®Google Scholar
• Polakis P. Wnt signaling and cancer. Genes Dev. 2000;14(15):1837–1851.
   PubMed Web of Science ®Google Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer. 2013;13(3):184–199.
   PubMed Web of Science ®Google Scholar
• O’Neill JP, Shaha AR. Anaplastic thyroid cancer. Oral Oncol. 2013;49(7):702–706.
   PubMed Web of Science ®Google Scholar
• Anastas JN, Moon RT. WNT signalling pathways as therapeutic targets in cancer. Nat Rev Cancer. 2013;13(1):11–26.
   PubMed Web of Science ®Google Scholar
• Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(Suppl 2):21–26.
   PubMed Web of Science ®Google Scholar
• Knauf JA. Does the epidermal growth factor receptor play a role in the progression of thyroid cancer? Thyroid. 2011;21(11):1171–1174.
   PubMed Web of Science ®Google Scholar
• Yeh MW, Rougier JP, Park JW, et al. Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A. Endocr Relat Cancer. 2006;13(4):1173–1183.
   PubMed Web of Science ®Google Scholar
• Liu Z, Hou P, Ji M, et al. Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab. 2008;93(8):3106–3116.
   PubMed Web of Science ®Google Scholar
• Bond JA, Wyllie FS, Rowson J, et al. In vitro reconstruction of tumour initiation in a human epithelium. Oncogene. 1994;9(1):281–290.
   PubMed Web of Science ®Google Scholar
• Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25(4):581–611.
   PubMed Web of Science ®Google Scholar
• Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999;155(6):1967–1976.
   PubMed Web of Science ®Google Scholar
• Sato K. Vascular endothelial growth factors and thyroid disorders. Endocr J. 2001;48(6):635–646.
   PubMed Web of Science ®Google Scholar
• Lennard CM, Patel A, Wilson J, et al. Intensity of vascular endothelial growth factor expression is associated with increased risk of recurrence and decreased disease-free survival in papillary thyroid cancer. Surgery. 2001;129(5):552–558.
   PubMed Web of Science ®Google Scholar
• Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid. 2010;20(7):697–706.
   PubMed Web of Science ®Google Scholar
• Kelly LM, Barilab G, Liu P, et al. Identification of the transforming STRN-ALK fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. Proc Natl Acad Sci U S A. 2014;111(11):4233–4238.
   PubMed Web of Science ®Google Scholar
• Demeure MJ, Aziz M, Rosenberg R, et al. Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4-ALK translocation as a therapeutic target. World J Surg. 2014;38(6):1296–1305.
   PubMed Web of Science ®Google Scholar
• Nikiforov YE, Nikiforova MN. Molecular genetics and diagnosis of thyroid cancer. Nat Rev Endocrinol. 2011;7(10):569–580.
   PubMed Web of Science ®Google Scholar
• Placzkowski KA, Reddi HV, Grebe SK, et al. The role of the PAX8/PPARgamma fusion oncogene in thyroid cancer. PPAR Res. 2008;2008:672829.
   PubMed Web of Science ®Google Scholar
• Kim J, Lee Y, Cho HJ, et al. NTRK1 fusion in glioblastoma multiforme. PLoS One. 2014;9(3):e91940.
   PubMed Web of Science ®Google Scholar
• Vaishnavi A, Capelletti M, Le AT, et al. Oncogenic and drug-sensitive NTRK1 rearrangements in lung cancer. Nat Med. 2013;19(11):1469–1472.
   PubMed Web of Science ®Google Scholar
• Morrison JA, Pike LA, Sams SB, et al. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Mol Cancer. 2014;13:62.
   PubMed Web of Science ®Google Scholar
• Fagin JA, Matsuo K, Karmakar A, et al. High prevalence of mutations of the p53 gene in poorly differentiated human thyroid carcinomas. J Clin Invest. 1993;91(1):179–184.
   PubMed Web of Science ®Google Scholar
• Quiros RM, Ding HG, Gattuso P, et al. Evidence that one subset of anaplastic thyroid carcinomas are derived from papillary carcinomas due to BRAF and p53 mutations. Cancer. 2005;103(11):2261–2268.
   PubMed Web of Science ®Google Scholar
• Liu D, Yang C, Bojdani E, et al. Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst. 2013;105(21):1617–1627.
   PubMedGoogle Scholar
• Mahlknecht U, Hoelzer D. Histone acetylation modifiers in the pathogenesis of malignant disease. Mol Med. 2000;6(8):623–644.
   PubMed Web of Science ®Google Scholar
• Marks P, Rifkind RA, Richon VM, et al. Histone deacetylases and cancer: causes and therapies. Nat Rev Cancer. 2001;1(3):194–202.
   PubMed Web of Science ®Google Scholar
• Lin SF, Lin JD, Chou TC, et al. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment. PLoS One. 2013;8(10):e77684.
   PubMed Web of Science ®Google Scholar
• Chien W, Koeffler HP. Molecular biology of thyroid cancer. Thyroid Cancer. 2012;30:35–43.
   Google Scholar
• Marini F, Luzi E, Brandi ML. MicroRNA role in thyroid cancer development. J Thyroid Res. 2011;2011:407123.
   PubMedGoogle Scholar
• Xiong Y, Zhang L, Kebebew E. MiR-20a is upregulated in anaplastic thyroid cancer and targets LIMK1. PLoS One. 2014;9(5):e96103.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhang KY, Liu SM, et al. Tumor-associated circulatingMicroRNAs as biomarkers of cancer. Molecules. 2014;19(2):1912–1938.
   PubMed Web of Science ®Google Scholar
• Guo Z, Hardin H, Lloyd RV. Cancer stem-like cells and thyroid cancer. Endocr Relat Cancer. 2014;21(5):T285–300.
   PubMed Web of Science ®Google Scholar
• Gao YJ, Li B, Wu XY, et al. Thyroid tumorinitiating cells: increasing evidence and opportunities for anticancer therapy (Review). Oncol Rep. 2014;31(3):1035–1042.
   PubMed Web of Science ®Google Scholar
• Nagayama Y, Shimamura M, Mitsutake N. Cancer stem cells in the thyroid. Front Endocrinol (Lausanne). 2016;7:20.
   PubMed Web of Science ®Google Scholar
• Antonelli A, La Motta C. Novel therapeutic clues in thyroid carcinomas: the role of targeting cancer stem cells. Med Res Rev. 2017;37(6):1299–1317.
   PubMed Web of Science ®Google Scholar
• Heiden KB, Williamson AJ, Doscas ME, et al. The sonic hedgehog signaling pathway maintains the cancer stem cell self-renewal of anaplastic thyroid cancer by inducing snail expression. J Clin Endocrinol Metab. 2014;99(11):E2178–E2187.
   PubMed Web of Science ®Google Scholar
• Malaguarnera R, Frasca F, Garozzo A, et al. Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab. 2011;96(3):766–774.
   PubMed Web of Science ®Google Scholar
• Tseng LM, Huang PI, Chen YR, et al. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells. J Pharmacol Exp Ther. 2012;341:410–423.
   PubMed Web of Science ®Google Scholar
• Flaherty KT, Infante JR, Daud A, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012;367(18):1694–1703.
   PubMed Web of Science ®Google Scholar
• Kurata K, Onoda N, Noda S, et al. Growth arrest by activated BRAF and MEK inhibition in human anaplastic thyroid cancer cells. Int J Oncol. 2016;49(6):2303–2308.
   PubMed Web of Science ®Google Scholar
• Maverakis E, Cornelius LA, Bowen GM, et al. Metastatic melanoma - a review of current and future treatment options. Acta Derm Venereol. 2015;95(5):516–524.
   PubMed Web of Science ®Google Scholar
• Lim AM, Taylor GR, Fellowes A, et al. BRAF Inhibition in BRAFV600E-positive anaplastic thyroid carcinoma. J Natl Compr Canc Netw. 2016;14(3):249–254.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Busaidy NL, Khan SA, et al. Molecular diagnostics and anaplastic thyroid carcinoma: the time has come to harvest the high hanging fruit. Int J Endocr Oncol. 2016;3(3):221–233.
   Web of Science ®Google Scholar
• Subbiah V, Bang YJ, Lassen UN, et al. ROAR: a phase 2, open-label study in patients (pts) with BRAF V600E–mutated rare cancers to investigate the efficacy and safety of dabrafenib (D) and trametinib (T) combination therapy. J Clin Oncol. 2016. Abstract TPS2604.
   Google Scholar
• [No authors listed]. Dabrafenib plus trametinib is active in BRAFV600E anaplastic thyroid cancer. Cancer Discov. 2018;8(1):9.
   Web of Science ®Google Scholar
• Subbiah V, Kreitman RJ, Wainberg ZA, et al. Dabrafenib and trametinib treatment in patients with locally advanced or metastatic BRAF V600-mutant anaplastic thyroid cancer. J Clin Oncol. 2018;36(1):7–13.
   PubMed Web of Science ®Google Scholar
• Cabanillas ME, Ferrarotto R, Garden AS, et al. Neoadjuvant BRAF- and immune-directed therapy for anaplastic thyroid carcinoma. Thyroid. 2018;28(7):945–951.
   PubMed Web of Science ®Google Scholar
• Kim KB, Cabanillas ME, Lazar AJ, et al. Clinical responses to vemurafenib in patients with metastatic papillary thyroid cancer harboring BRAF(V600E) mutation. Thyroid. 2013;23(10):1277–1283.
   PubMed Web of Science ®Google Scholar
• Rosove MH, Peddi PF, Glaspy JA. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013;368(7):684–685.
   PubMed Web of Science ®Google Scholar
• Prager GW, Koperek O, Mayerhoefer ME, et al. Sustained response to vemurafenib in a BRAFV600E-Mutated anaplastic thyroid carcinoma patient. Thyroid. 2016;26(10):1515–1516.
   PubMed Web of Science ®Google Scholar
• Marten KA, Gudena VK. Use of vemurafenib in anaplastic thyroid carcinoma: a case report. Cancer Biol Ther. 2015;16(10):1430–1433.
   PubMed Web of Science ®Google Scholar
• Hyman DM, Puzanov I, Subbiah V, et al. Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations. N Engl J Med. 2015;373(8):726–736.
   PubMed Web of Science ®Google Scholar
• Croyle M, Akeno N, Knauf JA, et al. RET/PTC-induced cell growth is mediated in part by epidermal growth factor receptor (EGFR) activation: evidence for molecular and functional interactions between RET and EGFR. Cancer Res. 2008;68(11):4183–4191.
   PubMed Web of Science ®Google Scholar
• Lopez JP, Wang-Rodriguez J, Chang CY, et al. Gefitinib (Iressa) potentiates the effect of ionizing radiation in thyroid cancer cell lines. Laryngoscope. 2008;118(8):1372–1376.
   PubMed Web of Science ®Google Scholar
• Nobuhara Y, Onoda N, Yamashita Y, et al. Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines. Br J Cancer. 2005;92(6):1110–1116.
   PubMed Web of Science ®Google Scholar
• Fury MG, Solit DB, Su YB, et al. A phase I trial of intermittent high-dose gefitinib and fixed-dose docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2007;59(4):467–475.
   PubMed Web of Science ®Google Scholar
• Wells SA Jr, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010;28(5):767–772.
   PubMed Web of Science ®Google Scholar
• Thornton K, Kim G, Maher VE, et al. Vandetanib for the treatment of symptomatic or progressive medullary thyroid cancer in patients with unresectable locally advanced or metastatic disease: U.S. Food and Drug Administration drug approval summary. Clin Cancer Res. 2012;18(14):3722–3730.
   PubMed Web of Science ®Google Scholar
• Wunderlich A, Khoruzhyk M, Roth S, et al. Pretherapeutic drug evaluation by tumor xenografting in anaplastic thyroid cancer. J Surg Res. 2013;185(2):676–683.
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol. 2012;13(9):897–905.
   PubMed Web of Science ®Google Scholar
• Sherman SI, Jarzab B, Cabanillas ME, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol. 2011. Abstract 5503.
   Web of Science ®Google Scholar
• Tohyama O, Matsui J, Kodama K, et al. Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models. J Thyroid Res. 2014;2014:638747.
   PubMedGoogle Scholar
• Takahashi S, Kiyota N, Yamazaki T, et al. Phase II study of lenvatinib in patients with differentiated, medullary, and anaplastic thyroid cancer: final analysis results. J Clin Oncol. 2016. Abstract 6088.
   PubMed Web of Science ®Google Scholar
• Tahara M, Kiyota N, Yamazaki T, et al. Lenvatinib for anaplastic thyroid cancer. Front Oncol. 2017;7:25.
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp MV, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol. 2009;27(10):1675–1684.
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 2008;26(29):4714–4719.
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol. 2009;161(6):923–931.
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet. 2014;384(9940):319–328.
   PubMed Web of Science ®Google Scholar
• Savvides P, Nagaiah G, Lavertu P, et al. Phase II trial of sorafenib in patients with advanced anaplastic carcinoma of the thyroid. Thyroid. 2013;23(5):600–604.
   PubMed Web of Science ®Google Scholar
• Ito Y, Onoda N, Ito KI, et al. Sorafenib in Japanese patients with locally advanced or metastatic medullary thyroid carcinoma and anaplastic thyroid carcinoma. Thyroid. 2017;27(9):1142–1148.
   PubMed Web of Science ®Google Scholar
• Chen G, Nicula D, Renko K, et al. Synergistic anti-proliferative effect of metformin and sorafenib on growth of anaplastic thyroid cancer cells and their stem cells. Oncol Rep. 2015;33(4):1994–2000.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol. 2008;26(29):4708–4713.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Tortorici M, Kim S, et al. A phase II trial of axitinib in patients with various histologic subtypes of advanced thyroid cancer: long-term outcomes and pharmacokinetic/pharmacodynamic analyses. Cancer Chemother Pharmacol. 2014;74(6):1261–1270.
   PubMed Web of Science ®Google Scholar
• Kim DW, Jo YS, Jung HS, et al. An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases. J Clin Endocrinol Metab. 2006;91(10):4070–4076.
   PubMed Web of Science ®Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res. 2010;16(21):5260–5268.
   PubMed Web of Science ®Google Scholar
• Ravaud A, de la Fouchardière C, Caron P, et al. A multicenter phase II study of sunitinib in patients with locally advanced or metastatic differentiated, anaplastic or medullary thyroid carcinomas: mature data from the THYSU study. Eur J Cancer. 2017;76:110–117.
   PubMed Web of Science ®Google Scholar
• Grande E, Capdevila J, Díez JJ, et al. A significant response to sunitinib in a patient with anaplastic thyroid carcinoma. J Res Med Sci. 2013;18(7):623–625.
   PubMed Web of Science ®Google Scholar
• Cohen EE, Needles BM, Cullen KJ, et al. Phase 2 study of sunitinib in refractory thyroid cancer. J Clin Oncol. 2008. Abstract 6025.
   Google Scholar
• Goulart B, Carr L, Martins RG, et al. Phase II study of sunitinib in iodine refractory, well-differentiated thyroid cancer (WDTC) and metastatic medullary thyroid carcinoma (MTC). J Clin Oncol. 2008. Abstract 6062.
   Google Scholar
• Antonelli A, Bocci G, La Motta C, et al. CLM94, a novel cyclic amide with anti-VEGFR-2 and antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2012;97(4):E528–E536.
   PubMed Web of Science ®Google Scholar
• Ferrari SM, Fallahi P, La Motta C, et al. Antineoplastic activity of the multitarget tyrosine kinase inhibitors CLM3 and CLM94 in medullary thyroid cancer in vitro. Surgery. 2014;156(5):1167–1176.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Bocci G, Fallahi P, et al. CLM3, a multitarget tyrosine kinase inhibitor with antiangiogenic properties, is active against primary anaplastic thyroid cancer in vitro and in vivo. J Clin Endocrinol Metab. 2014;99(4):E572–E581.
   PubMed Web of Science ®Google Scholar
• Fallahi P, Ferrari SM, La Motta C, et al. CLM29 and CLM24, pyrazolopyrimidine derivatives, have antitumoral activity in vitro in anaplastic thyroid cancer, with or without BRAF mutation. Endocrine. 2016;53(1):136–144.
   PubMed Web of Science ®Google Scholar
• Kanthou C, Tozer GM. Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol. 2009;90(3):284–294.
   PubMed Web of Science ®Google Scholar
• Dowlati A, Robertson K, Cooney M, et al. A phase I pharmacokinetic and translational study of the novel vascular targeting agent combretastatin a-4 phosphate on a single-dose intravenous schedule in patients with advanced cancer. Cancer Res. 2002;62(12):3408–3416.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Balkissoon J, Lu SP, et al. Thyroidectomy followed by fosbretabulin (CA4P) combination regimen appears to suggest improvement in patient survival in anaplastic thyroid cancer. Surgery. 2012;152(6):1078–1087.
   PubMed Web of Science ®Google Scholar
• Sosa JA, Elisei R, Jarzab B, et al. Randomized safety and efficacy study of fosbretabulin with paclitaxel/carboplatin against anaplastic thyroid carcinoma. Thyroid. 2014;24(2):232–240.
   PubMed Web of Science ®Google Scholar
• Onoda N, Sugino K, Higashiyama T, et al. The safety and efficacy of weekly paclitaxel administration for anaplastic thyroid cancer patients: a nationwide prospective study. Thyroid. 2016;26(9):1293–1299.
   PubMed Web of Science ®Google Scholar
• Keir ME, Butte MJ, Freeman GJ, et al. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
   PubMed Web of Science ®Google Scholar
• Ahn S, Kim TH, Kim SW, et al. Comprehensive screening for PD-L1 expression in thyroid cancer. Endocr Relat Cancer. 2017;24(2):97–106.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012;366(26):2443–2454.
   PubMed Web of Science ®Google Scholar
• Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regression and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer. Oncotarget. 2016;7(13):17194–17211.
   PubMedGoogle Scholar
• Iyer PC, Dadu R, Gule-Monroe M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma. J Immunother Cancer. 2018;6(1):68.
   PubMedGoogle Scholar
• Hayashi N, Nakamori S, Hiraoka N, et al. Antitumor effects of peroxisome proliferator activate receptor gamma ligands on anaplastic thyroid carcinoma. Int J Oncol. 2004;24(1):89–95.
   PubMed Web of Science ®Google Scholar
• Marlow LA, Reynolds LA, Cleland AS, et al. Reactivation of suppressed RhoB is a critical step for the inhibition of anaplastic thyroid cancer growth. Cancer Res. 2009;69(4):1536–1544.
   PubMed Web of Science ®Google Scholar
• Aiello A, Pandini G, Frasca F, et al. Peroxisomal proliferator-activated receptor-gamma agonists induce partial reversion of epithelial-mesenchymal transition in anaplastic thyroid cancer cells. Endocrinology. 2006;147:4463–4475.
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. Dedifferentiated thyroid cancer: a therapeutic challenge. Biomed Pharmacother. 2008;62(8):559–563.
   PubMed Web of Science ®Google Scholar
• Chung SH, Onoda N, Ishikawa T, et al. Peroxisome proliferator-activated receptor gamma activation induces cell cycle arrest via the p53-independent pathway in human anaplastic thyroid cancer cells. Jpn J Cancer Res. 2002;93(12):1358–1365.
   PubMedGoogle Scholar
• Smallridge RC, Copland JA, Brose MS, et al. Efatutazone, an oral PPAR-γ agonist, in combination with paclitaxel in anaplastic thyroid cancer: results of a multicenter phase 1 trial. J Clin Endocrinol Metab. 2013;98(6):2392–2400.
   PubMed Web of Science ®Google Scholar
• Hombach-Klonisch S, Natarajan S, Thanasupawat T, et al. Mechanisms of therapeutic resistance in cancer (stem) cells with emphasis on thyroid cancer cells. Front Endocrinol (Lausanne). 2014;5:37.
   PubMed Web of Science ®Google Scholar
• Vicari L, Colarossi C, Giuffrida D, et al. Cancer stem cells as a potential therapeutic target in thyroid carcinoma. Oncol Lett. 2016;12(4):2254–2260.
   PubMed Web of Science ®Google Scholar
• Newell DR. Flasks, fibres and flanks–pre-clinical tumour models for predicting clinical antitumour activity. Br J Cancer. 2001;84(10):1289–1290.
   PubMed Web of Science ®Google Scholar
• Schroyens W, Tueni E, Dodion P, et al. Validation of clinical predictive value of in vitro colorimetric chemosensitivity assay in head and neck cancer. Eur J Cancer. 1990;26(7):834–838.
   PubMed Web of Science ®Google Scholar
• Blumenthal RD, Goldenberg DM. Methods and goals for the use of in vitro and in vivo chemosensitivity testing. Mol Biotechnol. 2007;35(2):185–197.
   PubMed Web of Science ®Google Scholar